Obstructive sleep disordered breathing in 2-to 18-year-old children: diagnosis and management

…, R Ersu, K Joosten, H Larramona… - European …, 2016 - Eur Respiratory Soc
This document summarises the conclusions of a European Respiratory Society Task Force
on the diagnosis and management of obstructive sleep disordered breathing (SDB) in …

ERS statement on obstructive sleep disordered breathing in 1-to 23-month-old children

…, R Ersu, K Joosten, H Larramona… - European …, 2017 - Eur Respiratory Soc
The present statement was produced by a European Respiratory Society Task Force to
summarise the evidence and current practice on the diagnosis and management of obstructive …

How do we recognize the child with OSAS?

KF Joosten, H Larramona, S Miano… - Pediatric …, 2017 - Wiley Online Library
Obstructive sleep‐disordered breathing includes a spectrum of clinical entities with variable
severity ranging from primary snoring to obstructive sleep apnea syndrome (OSAS). The …

Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study

…, C Brun, N Capdevila, H Larramona… - Journal of Pediatric …, 2019 - degruyter.com
Background There is little evidence of the effects of early treatment with growth hormone (GH)
in infants with Prader-Willi syndrome (PWS). A prospective study was conducted to assess …

Body plethysmography (i): Standardisation and quality criteria

I de Mir Messa, OS Prado, H Larramona… - Anales de Pediatría …, 2015 - Elsevier
Whole body plethysmography is used to measure lung volumes, capacities and resistances.
It is a well standardised technique, and although it is widely used in paediatric chest …

Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma

…, M Indiveri, R Ayats, H Larramona… - Allergologia et …, 2022 - all-imm.com
Background: In most cases, severe asthma in children has an allergic etiology, but allergen-specific
immunotherapy (AIT) is contraindicated. Objective: This study aimed at analyzing the …

Decision-making for pediatric allergy immunotherapy for aeroallergens: a narrative review

…, M Mesa del Castillo, H Larramona… - European Journal of …, 2019 - Springer
There has been exciting progress in diagnosis and in the treatment of allergic patients. The
objective of this review is to summarize the most relevant contributions in the past 10 years …

[HTML][HTML] Long-term outcome of omalizumab-assisted desensitisation to cow's milk and eggs in patients refractory to conventional oral immunotherapy: real-life study

…, M García-González, H Larramona-Carrera… - Allergologia et …, 2022 - all-imm.com
Background: Oral immunotherapy (OIT) is a promising approach to cow’s milk and egg
allergies, but reactions are frequent and some patients cannot be desensitized. Objective: To …

PD42-Is rituximab a trigger for persistent hypogammaglobulinemia in idiopathic nephrotic syndrome?

…, X Domingo, L Valdesoiro, H Larramona - Clinical and …, 2014 - Springer
Rituximab (RTX) is a monoclonal antibody; recently it has been use as a new treatment
strategy in patients with high-degree steroid-dependent nephrotic syndrome. It provokes a …

Induced sputum versus exhaled nitric oxide for the evaluation of airway inflammation in allergic pediatric asthma patients treated with omalizumab

X Domingo, M Bosque, L Valdesoiro, H Larramona… - Chest, 2013 - journal.chestnet.org
PURPOSE: To determine the inflammatory changes in the airways of allergic pediatric asthma
patients treated with omalizumab, measured by the percentage of eosinophil in induced …